Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825346 | 1.00 | CCKBR (0.52) | CCKBRCCKAR | |
| SCHEMBL1394657 | 0.99 | CCKBR (0.51) | CCKBRCCKAR | |
| Water SCHEMBL1394815 | 0.99 | CCKBR (0.51) | CCKBRCCKAR | |
| SCHEMBL6175868 | 0.93 | CCKBR (0.58) | CCKBRCCKAR | |
| SCHEMBL542390 | 0.91 | CCKBR (0.49) | CCKBRCCKAR | |
| SCHEMBL6179081 | 0.91 | CCKBR (0.50) | CCKBRCCKAR | |
| SCHEMBL6177621 | 0.91 | CCKBR (0.49) | CCKBRCCKAR | |
| SCHEMBL6177764 | 0.90 | CCKAR (0.59) | CCKBRCCKAR | |
| SCHEMBL6176921 | 0.90 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL542264 | 0.90 | CCKBR (0.48) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | CCKBR 1/4885CCKAR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.